|2.||Headache Disorders (Headache Syndromes)
|3.||Tension-Type Headache (Tension Headache)
|5.||Migraine Disorders (Migraine)
|1.||Jones, Jeremy C: 1 article (02/2014)|
|2.||Ross, Edgar L: 1 article (02/2014)|
|3.||Hassanzadeh, Roya: 1 article (02/2014)|
|4.||Fiorillo, M: 1 article (12/2011)|
|5.||Rocchietti-March, M: 1 article (12/2011)|
|6.||Negro, A: 1 article (12/2011)|
|7.||Martelletti, P: 1 article (12/2011)|
|8.||Shapiro, Robert E: 1 article (08/2008)|
|9.||Sahin, Sevki: 1 article (04/2008)|
|10.||Savrun, Feray Karaali: 1 article (04/2008)|
|1.||Analgesics (Analgesic Drugs)IBA
01/01/1996 - "Frequent, excessive use of over-the-counter or prescription analgesics may lead to analgesic rebound headache. "
11/01/1993 - "Overuse of analgesics is usually a part of this clinical picture, which has been termed "analgesic rebound headache." Fifty-three of the first 100 patients admitted to a community hospital's inpatient headache treatment program had chronic daily headaches and were overusing analgesics or other headache relief medications. "
09/01/1998 - "Discontinuing daily analgesics, with the concomitant use of amitriptyline, is an effective treatment for analgesic rebound headache in this population."
04/01/2002 - "In the United States analgesic-overuse headache is often caused by butalbital-containing analgesics. "
12/01/2011 - "Misuse of ergots, triptans, opioids or combination analgesics on > or = 10 days/month was required to make the diagnosis of MOH, while > or = 15 days/month were needed for simple analgesic-overuse headache. "
|2.||Amitriptyline (Elavil)FDA LinkGeneric
|3.||Ergotamine (Ergotamine Tartrate)FDA LinkGeneric
04/01/2008 - "Twenty-three female patients with probable ergotamine- overuse headache (PEOH), 23 female patients with probable analgesic-overuse headache (PAOH), and 15 healthy female controls participated in the study. "
05/01/2006 - "We found a significant decrease in the relative frequency of probable ergotamine overuse headache (from 18.6% to 0%, P < .0001), and in probable combination analgesic overuse headache (from 42.2% to 13.6%, P < .0001). "
12/01/2003 - "In 80% of patients codeine was the predominant agent implicated in the analgesic rebound headaches (mean 1053 mg/week) and 24% used ergotamine-containing medications (mean 16 mg/week). "
|4.||Glutamic Acid (Glutamate)FDA Link
|5.||Neurotransmitter Agents (Neurotransmitter)IBA
|7.||Codeine (Codeine Phosphate)FDA LinkGeneric
02/01/1994 - "These parameters were further evaluated with respect to a variety of subgroups: 1) migraine alone 2) migraine with co-existent tension-type headache 3) drug-induced headache (analgesic rebound headache) 4) posttraumatic headache 5) preventive versus no preventive medication 6) presence or absence of adverse events 7) presence or absence of recurrence and 8) average duration of migraine with no medication."
|9.||Caffeine (No Doz)FDA LinkGeneric
|10.||Opioid Analgesics (Opioids)IBA
|1.||Drug Therapy (Chemotherapy)